On Apr. 10, 2020, BenevolentAI announced that baricitinib, which it had identified as a potential treatment for COVID-19, will enter late stage phase 3 clinical trials to treat the disease. This new trial is occurring alongside a Canadian government-sponsored randomised-controlled trial already underway of baricitinib as a potential treatment.

Baricitinib is an already approved drug developed by Eli Lilly and Incyte for the treatment of rheumatoid arthritis and is being studied for other indications.